ZLNA ZELLUNA ASA

Zelluna ASA – Ex. date

Zelluna ASA – Ex. date

The shares in Zelluna ASA will from today, 4 November 2025, be traded exclusive of the right to participate in the contemplated subsequent offering announced on 3 November 2025.

This information is published in accordance with the requirements of the Continuing Obligations for Euronext Oslo Børs.



 



EN
04/11/2025

Underlying

ZLNAZELLUNA ASA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ZELLUNA ASA

 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna Receives UK MHRA and Ethics Approval to Initiate ZIMA-101 Firs...

Zelluna Receives UK MHRA and Ethics Approval to Initiate ZIMA-101 First-in-Human Clinical Trial Regulatory clearance enables start of clinical testing and marks transition to clinical-stage companyOn track for initial clinical data to emerge from mid-2026 Oslo, Norway, 20 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) and Research Ethics Committee (REC) has approved the Comp...

February 20, 2026 1 EN
 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna mottar UK MHRA og etisk godkjenning for oppstart av ZIMA-101 f...

Zelluna mottar UK MHRA og etisk godkjenning for oppstart av ZIMA-101 første-i-menneske klinisk studie Regulatorisk godkjenning muliggjør oppstart av klinisk testing og markerer overgang til klinisk faseFørste kliniske data forventes fra medio 2026 Oslo, Norge, 20 februar 2026 – Zelluna (OSE: ZLNA) utvikler allogene "off-the-shelf" T-cellereseptor-baserte naturlige dreperceller (TCR-NK) for behandling av solide kreftformer. Selskapet kunngjør i dag at Medicines and Healthcare products Regulatory Agency (MHRA) og Research Ethics Committee (REC) i Storbritannia har godkjent selskapets søkna...

February 20, 2026 1 EN
 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna ASA: Fourth Quarter 2025 – Key regulatory milestone achieved w...

Zelluna ASA: Fourth Quarter 2025 – Key regulatory milestone achieved with CTA Submission Oslo, 12 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today presents its results for the fourth quarter and full year 2025. Webcast scheduled for 12 February 2026, at 08:30 (CET). Link to webcast . Operational Highlights Q4 2025 CTA submitted: On 17 December 2025, Zelluna submitted its first Clinical Trial Application (CTA) to the UK MHRA for ZI-MA4-1, the world's ...

February 12, 2026 1 EN
 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna ASA: Fjerde kvartal 2025 – Viktig regulatorisk milepæl oppnådd...

Zelluna ASA: Fjerde kvartal 2025 – Viktig regulatorisk milepæl oppnådd med CTA-innlevering Oslo, 12. februar 2026 – Zelluna (OSE: ZLNA), et selskap som utvikler allogene "off-the-shelf" T-cellereseptor-baserte Natural Killer (TCR-NK) celleterapier for behandling av kreft, presenterer i dag resultatene for fjerde kvartal og året 2025. Webcast er planlagt 12. februar 2026 kl. 08:30 (CET). Lenke til webcast . Operasjonelle høydepunkter Q4 2025: CTA innlevert: 17. desember 2025 leverte Zelluna sin første søknad om oppstart av klinisk studie (Clinical Trial Application, CTA) til UK MH...

February 12, 2026 1 EN
 PRESS RELEASE
Free
ZLNA ZELLUNA ASA

Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical tr...

Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical trial Global CRO to support execution of ZIMA-101 study with world's first MAGE-A4-targeting TCR-NK cell therapy productPartnership follows submission of the Clinical Trial Application (CTA) to the MHRA Oslo, Norway – 11 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced a clinical partnership with Medpace, a leading global Contract Research Organization (CRO), to support the f...

February 11, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch